Matthew S. Davids, MD, MMSc, on TP53-Aberrant CLL: Combination of Acalabrutinib, Venetoclax, and Obinutuzumab

Posted: Monday, February 3, 2025

Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Harvard Medical School, shares a brief update on a phase II trial of the triplet regimen of acalabrutinib, venetoclax, and obinutuzumab in patients with TP53-aberrant chronic lymphocytic leukemia (CLL). He also offers his perspective on whether this acalabrutinib combination therapy has the potential to become a new standard of care for this type of hematologic malignancy.

---